Q4 revenues grew 17.2% YoY to | 457.5 crore (I-direct estimate: | 450.3 crore) on account of 20.7% YoY growth in the pharma segment to | 259.2 crore (I-direct estimate: | 268.4 crore) and 12.8% YoY growth in the crop protection segment to | 198.4 crore (I-direct estimate: | 175.8 crore). EBITDA margins remained at ~18.4%, (I-direct estimate: 19.2%). The fall in gross margins (75.8% vs. 79.3% in Q4FY18) was offset by a decline in employee cost and other expenditure. EBITDA grew 17.5% YoY to | 84 crore vis--vis I-direct estimate of | 86.6 crore. Net profit grew 31.6% YoY to | 33.3...